Stockreport

From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside [Seeking Alpha]

uniQure N.V. - Ordinary Shares  (QURE) 
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: uniqure.com/investors-newsroom/overview.php
PDF AMT-130 is the first disease-modifying therapy for Huntington's, showing 75% slowing of disease progression and significant functional benefit in Phase 1/2 data. Mode [Read more]